Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Cell and gene therapy 4

Cell and Gene Therapy

recent-pharma-happenings-for-recursion-repertoire-cequr-eli-lilly

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Lilly’s Retevmo shows promise; CeQur tanks up on $110M in funding; Repertoire secures $189M; Recursion sets terms for $306M IPO

Lilly’s RET inhibitor Retevmo exhibits early promise in new cancer types The phase 1/2 LIBRETTO-001 trial enrolled 32 patients with 12 unique RET fusion-positive advanced cancer types, comprising pancreatic, colon, breast and salivary cancer, with 62.5% affected by gastrointestinal tumours. Across all 32 patients who administered Retevmo (selpercatinib), the researchers noticed a confirmed objective response rate (ORR) of 47%, with the median duration of response not yet reach with a follow-up of 13 months. As per Lilly, responses were ongoing in 73% of responding patients in the study. David Hyman, chief medical officer, oncology at Lilly, said that these en...

Explore More...

Gene therapy

Can commoners afford to spend million dollars on GENE Therapy?

gene therapy in oncology

Gene Therapy in Oncology: Innovation to Commercialization

The Business Cocktail

Inozyme Raises $67M; Shanghai Miracogen partners with Synaffix; EdiGENE raises $15M; Antengene announces its expansion

Gene Therapy in Oncology

The promising Pipeline for Gene Therapy In Oncology

stem cell therapy

Notizia

merck

The Business Cocktail

mRNA

BioNTech lines up $800M; Deerfield remunerates; Britain’s Smith & Nephew to acquire Osiris

The Business Cocktail

CRISPR

Notizia

CRISPR

A CRISPR WAY TO USE STEM CELLS

CRISPR

CRISPR proves to be a blessing for LASSA fever

Kidney Cancer

Notizia

Diabetes

Human cells reprogrammed to create insulin in diabetic mice

Peloton Therapeutics

Neurogene raises $68.5M; AbbVie and Teneobio sign deal; 5AM Ventures nets

Genentech remunerates Xencor; XPrize upraises fund; GSK gambles

Kidney Cancer

Notizia

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly